Sartorius to Sell Its Industrial Technologies Division to Minebea
Sartorius is selling its Industrial Technologies Division (Intec) to the Japanese Minebea Co., Ltd and their partner, the Development Bank of Japan Inc. The sales price will be determined as a multiple of the Intec division’s 2014 operating profit and be fixed in early 2015. The contractual parties agreed on a 7.5 multiple on the division’s 2014 operating EBITDA. The transaction is subject to customary closing conditions, including regulatory clearance by the antitrust authorities, and is expected to close in the first quarter of 2015.
“By selling our Intec Division to Minebea, we are realizing an important cornerstone of our long-term strategy and focus on our two core activities in bioprocess and laboratory. Over the past years we have successfully positioned our Intec business as a specialist for industrial weighing and control technologies and have reached healthy profitability levels. Under Minebea`s roof, this business will now gain the critical mass needed to further extend its footprint internationally, an important prerequisite for further growth. I am convinced that Minebea is the perfect new owner for this business because of the complementarity of the product portfolios and the geographical footprint, and also because of their commitment to long-term strategies and premium products,” commented Joachim Kreuzburg, CEO and Chairman of the Executive Board of Sartorius.
The smallest division in the Sartorius Group, Intec recorded sales revenue of €102 million for fiscal 2013; its underlying EBITDA margin attained 10.1% at year-end in the prior reporting period. The division employs around 700 people worldwide, 350 of whom work at its German sites in Hamburg, Aachen and Bovenden. The Intec business will complement the Measurement Components business unit at Minebea, which will take on all Intec Division staff.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...